Dr. Komissarov earned both his MS and PhD degree at the Lomonosov Moscow State University and served as an Assistant Professor in the Chemistry Department. After over a decade at the Moscow State University he joined the Institute for Genetics and Selection of Industrial Microorganisms—now a part of the Federal Kurchatov Center— as a Senior Scientist, where he applied his experience in enzymology and protein chemistry to developing novel anti-cancer therapeutics. Prior to joining the University of Texas Health Science Center at Tyler (UTHSCT) in 2007 Dr. Komissarov conducted his research at the University of Missouri, Columbia; HFHS, Detroit; and Portland State University. His philosophy in research is - collaboration. He believes that forming a team of cooperating experts is the most effective approach in moving modern translational science forward. Dr. Komissarov brought to UT Tyler/UTHSCT (joined in 2007) his experience in understanding the molecular interactions in fibrinolysis and SERPIN biochemistry, which resulted in the identification of Plasminogen Activator Inhibitor 1 (PAI-1) as a Molecular Target in the pleural injury. PAI-1 targeting in preclinical studies has increased the efficacy of fibrinolytic therapy up to 8-fold.
Research
Dr. Komissarov focuses on identification and preclinical testing of novel inhibitors of PAI-1 to develop a Low Dose Targeted Fibrinolytic Therapy (LDTFT) amendable for translation to the clinical practice. His laboratory employs preclinical models to elucidate efficacy of fibrinolytic therapy with drugs encapsulated into echogenic fibrin targeted liposomal carriers and “molecular cage” type complexes. Dr. Komissarov is also interested in effect of ultrasound on therapeutic outcome. Targeted delivery of plasminogen activators using diverse types of liposomes, microfibers, and microparticles loaded with drugs is currently under evaluation in vitro, and ex vivo. Other projects include development of a rabbit model of retained hemothorax to test human pharmacologic interventions, as well as analyses of samples from COVID-19 patients subjected to the convalescent plasma treatment during CONTAIN clinical trial. Biotechnology projects in his laboratory are focused on development, formulation, characterization, and stabilization of novel therapeutics such as “manufacturing-friendly” small peptides selected from phage display libraries. His laboratory is working on a prototype of a novel Point of Care (POC) diagnostic test – the Fibrinolytic Potential Assay (FPA, US Patent #10175255) — to personalize therapy of empyema. Dr. Komissarov has co-authored more than 60 publications in peer-reviewed journals, here is a link to his bibliography: https://www.ncbi.nlm.nih.gov/myncbi/andrey.komissarov.1/bibliography/public/.
His research is currently supported by three MPI NIH/NHLBI Awards: two R01 (2R01HL130402 and 1R01 HL152059-01; 2021-2025) where Dr. Komissarov serves as a Contact PI, and one R33 (1R33HL154103-01; 2020-2022), where he serves as a PI.
Teaching
Dr. Komissarov’ teaching philosophy focuses on mentorship and providing early opportunities for personal development and professional advancement, age- and training-appropriate research experiences for young future scientists and medical professionals. The range spans from K-12 through undergraduate, graduate, and post-graduate levels. Every year mentees from Dr. Komissarov’ laboratory win scholarships and travel grants to take part in international and local meetings to present posters and talks (45 since 2017).
Education and Training
Moscow State University, Moscow, USSR
MS/BS, Chemistry, 1980
Moscow State University, Moscow, USSR
PhD, Chemistry of Natural Compounds, 1988
Courses Taught Biotechnology Master Program at UTHSCT, team lecturer;
BIOT 5221, Proteins and Nucleic Acids;
BIOT 5222, Advanced Metabolism;
BIOT 5222L, Advanced Metabolism (lab);
BIOT 5310, Fundamentals of Biomedical Research;
BIOT 6312, Advanced Techniques in Protein Chemistry;
BIOT 6312L, Advanced Techniques in Protein Chemistry (lab);
BIOT 5211, Advanced Biotechniques;
BIOT 5211L, Advanced Biotechniques (lab);
BIOT 5331, Advanced Graduate Studies I;
BIOT 5332, Advanced Graduate Studies II;
BIOT 6331, Thesis Research;
BIOT 6332, Thesis Writing;
BIOT 5132, Critical Reading; Graduate Students’ Mentor and Thesis Committee Member. Research Interests (i) Preclinical Testing and Optimization of a Novel Low-Dose Targeted Fibrinolytic Therapy for Infectious Pleural Injury.
(ii) Further Development and Commercialization of an Innovative Point of Care Fibrinolytic Potential Assay (US Patent #10175255) in Order to Personalize Fibrinolytic Therapy in Pleural Injury.
(iii) Preclinical Evaluation of Molecular Interactions of Fibrinolysis in Retained Hemothorax.
(iv) Study of Novel Molecular Mechanisms of Fibrinolysis and Modulation of SERPIN Reactions.
(v) Evaluation of Effects of Ultrasonography and Computed Tomography on Fibrinolysis and Fibrin Structure in vitro, ex vivo and in vivo.
Recent Publications 1. PAI-1 Drives Septation and Clinical Outcome in Pleural Infection. Komissarov, A.A. and Idell, S., Am J Respir Crit Care Med., Ahead of print, 2022.
2. From bedside to the bench – a call for novel approaches to prognostic evaluation and treatment of empyema. Karandashova, S., Florova, G., Idell, S., and Komissarov, A. A. Frontiers Pharm., v.12, 806393, 2022.
3. Precision Targeting of the PAI-1 Mechanism Increases Efficacy of Fibrinolytic Therapy in Empyema. G. Florova, R.A. Girard, A.O. Azghani, K. Sarva, A. Buchanan, S. Karandashova, C.J. DeVera, D. Morris, M. Chamiso, K. Koenig, D.B. Cines, S. Idell, and A.A. Komissarov Physiol Rep. 9(9): e14861, 2021.
4. Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression. Zhao R, Su Z, Komissarov AA, Liu SL, Yi G, Idell S, Matthay MA, Ji HL. Front Immunol. 2021 May 7;12:691249. doi: 10.3389/fimmu.2021.691249, 2021.
5. Sillen, M., Weeks, S., Zhou, X., Komissarov, A., Florova, G., Idell, S., Strelkov, S., Declerck, P. J. Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. J Thromb Haemost. 18: 681-692, 2020.
6. Wolfson, M. R., Enkhbaatar, P., Fukuda, S., Nelson, C. L., Williams, R. O. III, Hengsawas, S., Sahakijpijarn, S., Calendo, G., Komissarov, A. A., Florova, G., Sarva, K., Idell, S., Shaffer, T. H. Perfluorochemical‐Facilitated 1 Plasminogen Activator Delivery to the Airways: A Novel Treatment for Inhalational Smoke Induced Acute Lung Injury Running Head: Novel Treatment for Inhalational Smoke Acute Lung Injury. Clin Transl Med. 10(1):258-274, 2020.
MS/BS, Chemistry, 1980
Moscow State University, Moscow, USSR
PhD, Chemistry of Natural Compounds, 1988
Courses Taught Biotechnology Master Program at UTHSCT, team lecturer;
BIOT 5221, Proteins and Nucleic Acids;
BIOT 5222, Advanced Metabolism;
BIOT 5222L, Advanced Metabolism (lab);
BIOT 5310, Fundamentals of Biomedical Research;
BIOT 6312, Advanced Techniques in Protein Chemistry;
BIOT 6312L, Advanced Techniques in Protein Chemistry (lab);
BIOT 5211, Advanced Biotechniques;
BIOT 5211L, Advanced Biotechniques (lab);
BIOT 5331, Advanced Graduate Studies I;
BIOT 5332, Advanced Graduate Studies II;
BIOT 6331, Thesis Research;
BIOT 6332, Thesis Writing;
BIOT 5132, Critical Reading; Graduate Students’ Mentor and Thesis Committee Member. Research Interests (i) Preclinical Testing and Optimization of a Novel Low-Dose Targeted Fibrinolytic Therapy for Infectious Pleural Injury.
(ii) Further Development and Commercialization of an Innovative Point of Care Fibrinolytic Potential Assay (US Patent #10175255) in Order to Personalize Fibrinolytic Therapy in Pleural Injury.
(iii) Preclinical Evaluation of Molecular Interactions of Fibrinolysis in Retained Hemothorax.
(iv) Study of Novel Molecular Mechanisms of Fibrinolysis and Modulation of SERPIN Reactions.
(v) Evaluation of Effects of Ultrasonography and Computed Tomography on Fibrinolysis and Fibrin Structure in vitro, ex vivo and in vivo.
Recent Publications 1. PAI-1 Drives Septation and Clinical Outcome in Pleural Infection. Komissarov, A.A. and Idell, S., Am J Respir Crit Care Med., Ahead of print, 2022.
2. From bedside to the bench – a call for novel approaches to prognostic evaluation and treatment of empyema. Karandashova, S., Florova, G., Idell, S., and Komissarov, A. A. Frontiers Pharm., v.12, 806393, 2022.
3. Precision Targeting of the PAI-1 Mechanism Increases Efficacy of Fibrinolytic Therapy in Empyema. G. Florova, R.A. Girard, A.O. Azghani, K. Sarva, A. Buchanan, S. Karandashova, C.J. DeVera, D. Morris, M. Chamiso, K. Koenig, D.B. Cines, S. Idell, and A.A. Komissarov Physiol Rep. 9(9): e14861, 2021.
4. Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression. Zhao R, Su Z, Komissarov AA, Liu SL, Yi G, Idell S, Matthay MA, Ji HL. Front Immunol. 2021 May 7;12:691249. doi: 10.3389/fimmu.2021.691249, 2021.
5. Sillen, M., Weeks, S., Zhou, X., Komissarov, A., Florova, G., Idell, S., Strelkov, S., Declerck, P. J. Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction. J Thromb Haemost. 18: 681-692, 2020.
6. Wolfson, M. R., Enkhbaatar, P., Fukuda, S., Nelson, C. L., Williams, R. O. III, Hengsawas, S., Sahakijpijarn, S., Calendo, G., Komissarov, A. A., Florova, G., Sarva, K., Idell, S., Shaffer, T. H. Perfluorochemical‐Facilitated 1 Plasminogen Activator Delivery to the Airways: A Novel Treatment for Inhalational Smoke Induced Acute Lung Injury Running Head: Novel Treatment for Inhalational Smoke Acute Lung Injury. Clin Transl Med. 10(1):258-274, 2020.